Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Genetic Technologies Limited

Genetic Technologies Limited (GENE) Stock Overview

Explore Genetic Technologies Limited’s financial performance, market position, analyst ratings, and future outlook.

GENE●NASDAQ
HealthcareMedical - Diagnostics & Research
$0.77
$0.00(0.00%)
U.S. Market opens in 12h 45m

Genetic Technologies Limited (GENE)

Meyka AI Score

Z

Key Financials

Market Cap111.2M
P/E Ratio-0.40
EPS (TTM)$-0.02
ROE-1.85%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

GENE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Genetic Technologies Limited (NASDAQ: GENE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Genetic Technologies Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GENE on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind Genetic Technologies Limited's NASDAQ-traded stock include a P/E ratio of -0.40 and a market capitalization of 111.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of GENE on the NASDAQ.

Price Performance (NASDAQ: GENE)

1-Day Change
-0.65%
5-Day Change
-0.65%
1-Month Change
-0.65%
3-Month Change
-4.49%
6-Month Change
-57.97%
Year-to-Date (YTD) Change
-70.35%
1-Year Change
-75.48%
3-Year Change
-92.50%
5-Year Change
-92.92%
All-Time (Max) Change
-99.93%

Contact Information

https://www.gtglabs.com
61 3 8412 7000
60-66 Hanover Street, Fitzroy, VIC, 3065

Company Facts

550 Employees
IPO DateSep 6, 2005
CountryAU

Frequently Asked Questions